Table 2.
Characteristics of Liver Disease in 402 HCV RNA-Positive Patients
| HCV Genotype, n (%) | N = 402 |
| Unknown | 35 (8.7) |
| Known | 367 (91.3) |
| 1a | 143 (39.0) |
| 4 | 90 (24.5) |
| 1b | 69 (18.8) |
| 3 | 57 (15.5) |
| 2 | 5 (1.4) |
| Mixed | 3 (0.8) |
| IL28B polymorphism, n (%) | |
| Unknown | 235 (58.5) |
| Known | 167 (41.5) |
| CC | 49 (29.3) |
| CT | 89 (53.3) |
| TT | 29 (17.4) |
| Transient elastography (TE) results | |
| Patients with TE, n (%) | 345 (85.8) |
| Months from TE to study date, median (IQR) | 7.7 (3.5–15.5) |
| TE value – kPa, median (IQR) | 8.3 (5.9–13.0) |
| TE distribution according to cutoff values – kPa, n (%) | |
| <7.1 | 153 (44.3) |
| 7.1–9.5 | 41 (11.9) |
| 9.6–12.5 | 60 (17.4) |
| >12.5 | 91 (26.4) |
| FIB-4 results | |
| Patients with FIB-4, n (%) | 398 (99.0) |
| FIB-4 value, median (IQR) | 1.7 (1.2–2.7) |
| FIB-4 distribution according to cutoff values, n (%) | |
| ≤1 | 62 (15.6) |
| 1–3.25 | 265 (66.6) |
| ≥3.25 | 71 (17.8) |
| Anti-HCV therapy, n (%) | |
| Never | 233 (58.0) |
| Ongoing | 98 (24.4) |
| In the past | 71 (17.6) |
| Null response or partial response | 31 |
| Relapse | 22 |
| Discontinuation or interruption due to adverse events | 16 |
| Sustained viral responsea | 2 |
Abbreviations: FIB-4, fibrosis-4; HCV, hepatitis C virus; IQR, interquartile range; RNA, ribonucleic acid.
a Patients with HCV reinfection after successful treatment of hepatitis C.